CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -1.97: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
314.15MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9600xvs all stocks
52-Week Change
10.30%vs all stocks
Market Capitalization
314.15MUSDvs all stocks (USD)
Enterprise Value
185.87MUSDvs all stocks (USD)
Forward P/E
-5.31xvs Biotechnology peers
Price to Book (MRQ)
2.90xvs Biotechnology peers
Enterprise to EBITDA
-1.60xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-35.09%vs Biotechnology peers
Return on Equity (TTM)
-72.68%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-78.15MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-68.89MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.67MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-83.25MUSDvs all stocks (USD)
Pre-tax Income
-45.58MUSDFY2025 · Dec 31, 2025Income Tax Expense
35.00KUSDFY2025 · Dec 31, 2025Net Income
-45.62MUSDFY2025 · Dec 31, 2025EBIT
-83.25MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-116.39MUSDFY2025 · Dec 31, 2025Research & Development
66.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.98MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5200USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
81.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
81.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-45.62MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-28.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.81MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-45.62MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
313.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.45MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-313.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-161.13MUSDFY2025 · Dec 31, 2025Sale of Investments
171.93MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
10.79MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
53.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
75.85MSharesUpdated Jul 18, 2026Float Shares
69.93MSharesUpdated Jul 18, 2026Shares Short
7.83MSharesUpdated Jul 18, 2026Short Ratio
4.59daysvs all stocks
Short % of Shares Outstanding
10.15%vs all stocks
% Held by Insiders
1.09%vs all stocks
% Held by Institutions
59.36%vs all stocks
Total Cash (MRQ)
111.09MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.44USDUpdated Jul 18, 2026Total Debt (MRQ)
555.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0055xvs Biotechnology peers
Current Ratio (MRQ)
8.44xvs Biotechnology peers
Book Value per Share (MRQ)
1.32USDUpdated Jul 18, 2026Total Assets
169.01MUSDvs all stocks (USD)
Total Current Assets
135.69MUSDFY2025 · Dec 31, 2025Total Liabilities
87.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
33.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
18.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
110.53MUSDFY2025 · Dec 31, 2025Accounts Payable
3.63MUSDFY2025 · Dec 31, 2025Short-term Debt
358.00KUSDFY2025 · Dec 31, 2025Long-term Debt
283.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
75.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-401.20MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
81.08MUSDvs all stocks (USD)
52-Week Low
1.35USDUpdated Jul 18, 202652-Week High
4.60USDUpdated Jul 18, 202652-Week Change
10.30%vs all stocks
Beta
0.9600xvs all stocks
50-Day MA
3.79USDUpdated Jul 18, 2026200-Day MA
2.85USDUpdated Jul 18, 2026Avg 10-Day Volume
1.35MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.64MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.7300USDUpdated Jul 18, 2026Other Income / Expense
37.67MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 8.44Altman Z-Score: -1.97
Financial Health
Altman Z-Score -1.97: distress zoneCritical
Altman Z-Score: -1.97
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface